Grundium Acquires Visiopharm for AI Precision Pathology

Jan de Vries · 2026-05-25

A major shift just happened in the world of digital pathology. Grundium, a startup based in Tampere, Finland, has acquired Visiopharm, a Danish company that specializes in AI-driven precision pathology software. This deal is backed by EW Healthcare Partners, a US-based private equity firm focused on healthcare. The result? A combined platform that aims to make digital pathology more accessible and powerful for labs everywhere. ### What This Merger Means for Labs The merger brings together two pieces of a puzzle that often work separately. Grundium makes compact, high-quality digital pathology scanners. Think of them as the hardware that captures detailed images of tissue samples. Visiopharm provides the software that analyzes those images using artificial intelligence. Now, instead of piecing together tools from different vendors, labs can get an end-to-end solution from one company. This is a big deal for diagnostic labs, biopharma companies, and researchers. They can now move from sample to diagnosis faster, with fewer hiccups. The platform supports everything from small lab workflows to large enterprise deployments. It also helps with biomarker development, translational research, and clinical studies. Basically, it covers the whole chain. ### The People Behind the Tech Grundium was founded in 2015 by former Nokia engineers. That explains a lot about their focus on precision and reliability. Their Ocus series of microscope scanners are compact and affordable, which makes them a good fit for labs of any size. They claim these devices make remote pathology possible without sacrificing quality. Visiopharm has been around since 2002. It was started by Michael Grunkin and Johan Dore Hansen. Their software is already used in over 40 countries by more than 750 customers. In diagnostics, they have nine algorithms cleared under IVDR for EU customers. These tools help pathologists make decisions faster and more accurately. ### Why This Matters for Precision Medicine Precision medicine relies on accurate pathology. You can't treat a patient correctly if you don't know exactly what's happening at the cellular level. That's where this combination shines. Grundium's scanners capture high-res images, and Visiopharm's AI analyzes them for things like cancer markers. Together, they create a stronger foundation for personalized treatment. Mika Kuisma, CEO of Grundium, put it this way: "Precision medicine begins with precision pathology. By combining Grundium's imaging technologies with Visiopharm's advanced AI applications, we are creating a stronger foundation for physicians and laboratories to adopt high-value workflows." That's not just talk. The platform is designed to scale, so it can grow with a lab's needs. ### What Stays the Same for Customers Here's the good news for existing customers. Both companies will continue to support their current products independently. You don't have to switch to the combined platform if you don't want to. Grundium's scanners and Visiopharm's software will still work on their own. But if you want to integrate them, that option is now easier than ever. Andy Thomson from EW Healthcare Partners highlighted the potential: "Digital pathology has the potential to drastically improve diagnostic accuracy, workflow efficiency, and global access to expert care. The platform we are creating brings these capabilities together to make diagnosis faster, more reliable, and more efficient." He specifically mentioned oncology, where faster diagnosis can mean better outcomes. ### The Big Picture This acquisition is not just about two companies merging. It's about making digital pathology practical for more people. By lowering costs and removing infrastructure barriers, the combined platform opens doors for labs that couldn't afford high-end systems before. And with AI handling the heavy lifting, pathologists can focus on what they do best: interpreting results and guiding treatment. - Grundium provides the hardware: compact, high-precision scanners. - Visiopharm provides the software: AI-driven image analysis. - Together, they offer a complete solution for digital pathology. Both companies have already worked together in the past, integrating their solutions for labs. This acquisition just makes that partnership official and stronger. For anyone in the field of pathology, this is a development worth watching.